# SUMGEN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sumgen

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.sumgenbio.com
- Total disclosed funding: $40M
- Latest round: Series B (Dec 30, 2021)
- Investors on record: 11

## About

Founded in 2015 and based in Hangzhou, China, Hangzhou Sumgen Biotech Co., Ltd. trading as SUMGEN, is a biopharmaceutical company dedicated to the creation and commercialization of antibody therapeutics for cancer and other serious diseases. In December 2025, SUMGEN closed Series C funding from new investors Oriental Fortune Capital, Chime Biologics Limited Qijian Foundation.


The company develops an integrated process covering drug discovery, manufacturing, and clinical development. The company's main product pipeline is focused on broad immuno-oncology targets, with SG001, SG301, SG404, and SG12473 projects in the clinical study stage. It also offers a technology platform for antibody discovery for bispecific antibodies and deployed abundant innovative pipelines in the tumor field.

The company generates revenue by doing R&D, and providing innovative antibody drugs for the treatment of major diseases such as cancer and other related products.

The Series C funding raised in December 2025 will be used to advance the clinical development and industrialization of its pipeline drugs, further solidifying its innovative position in the field of therapeutic antibodies.

## Funding rounds

- Series B, Dec 30, 2021 — Zheshang Venture Capital, Addor Capital, Wanhuixin Fund, Hankang Capital, China National Biotec Group, Junchuan Capital
- Series B, Sep 13, 2020, $32M — BOCOM International Asset Management, Cowin Capital, Sinowisdom, Addor Capital, Dynamic Capital, Baopu Capital
- Series A, Jul 27, 2018, $7.3M — Hankang Capital

## Investors

- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series A, Series B
- BOCOM International Asset Management (https://capitalatlas.ai/funds/bocom-international-asset-management) — Series B
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Series B
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B
- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Series B
- Baopu Capital (https://capitalatlas.ai/funds/baopu-capital) — Series B
- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series B
- Wanhuixin Fund (https://capitalatlas.ai/funds/wanhuixin-fund) — Series B
- China National Biotec Group — Series B
- Junchuan Capital (https://capitalatlas.ai/funds/junchuan-capital) — Series B